Explore
Validate
Learn
ImmunohistochemistryAntibody data
- Antibody Data
- Antigen structure
- References [14]
- Comments [0]
- Validations
- Immunohistochemistry [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 200-301-A88 - Provider product page
- Provider
- Rockland Immunochemicals, Inc.
- Proper citation
- Rockland Cat#200-301-A88, RRID:AB_2147794
- Product name
- Anti-Mesothelin (MOUSE) Monoclonal Antibody - 200-301-A88
- Antibody type
- Monoclonal
- Vial size
- 100 µl
Submitted references Mesothelin/CD3 half-life extended bispecific T-cell engager molecule shows specific tumor uptake and distributes to mesothelin and CD3 expressing tissues.
Diffuse mesothelin expression leads to worse prognosis through enhanced cellular proliferation in colorectal cancer.
Single-Cell RNA Sequencing Identifies Yes-Associated Protein 1-Dependent Hepatic Mesothelial Progenitors in Fibrolamellar Carcinoma.
Live-Cell Mesothelioma Biobank to Explore Mechanisms of Tumor Progression.
Efficacy of Anti-mesothelin Immunotoxin RG7787 plus Nab-Paclitaxel against Mesothelioma Patient-Derived Xenografts and Mesothelin as a Biomarker of Tumor Response.
Combining Local Immunotoxins Targeting Mesothelin with CTLA-4 Blockade Synergistically Eradicates Murine Cancer by Promoting Anticancer Immunity.
Malignant Mesothelioma Effusions Are Infiltrated by CD3(+) T Cells Highly Expressing PD-L1 and the PD-L1(+) Tumor Cells within These Effusions Are Susceptible to ADCC by the Anti-PD-L1 Antibody Avelumab.
Reduced Shedding of Surface Mesothelin Improves Efficacy of Mesothelin-Targeting Recombinant Immunotoxins.
Mesothelin Expression in Advanced Gastroesophageal Cancer Represents a Novel Target for Immunotherapy.
Megakaryocytic potentiating factor and mature mesothelin stimulate the growth of a lung cancer cell line in the peritoneal cavity of mice.
Efficacy of RG7787, a next-generation mesothelin-targeted immunotoxin, against triple-negative breast and gastric cancers.
Loss of mesothelin expression by mesothelioma cells grown in vitro determines sensitivity to anti-mesothelin immunotoxin SS1P.
In vivo imaging of human malignant mesothelioma grown orthotopically in the peritoneal cavity of nude mice.
The development and characterization of a human mesothelioma in vitro 3D model to investigate immunotoxin therapy.
Suurs FV, Lorenczewski G, Bailis JM, Stienen S, Friedrich M, Lee F, van der Vegt B, de Vries EGE, de Groot DA, Lub-de Hooge MN
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2021 Apr 30;62(12):1797-804
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2021 Apr 30;62(12):1797-804
Diffuse mesothelin expression leads to worse prognosis through enhanced cellular proliferation in colorectal cancer.
Inoue S, Tsunoda T, Riku M, Ito H, Inoko A, Murakami H, Ebi M, Ogasawara N, Pastan I, Kasugai K, Kasai K, Ikeda H, Inaguma S
Oncology letters 2020 Mar;19(3):1741-1750
Oncology letters 2020 Mar;19(3):1741-1750
Single-Cell RNA Sequencing Identifies Yes-Associated Protein 1-Dependent Hepatic Mesothelial Progenitors in Fibrolamellar Carcinoma.
Jewell ML, Gibson JR, Guy CD, Hyun J, Du K, Oh SH, Premont RT, Hsu DS, Ribar T, Gregory SG, Diehl AME
The American journal of pathology 2020 Jan;190(1):93-107
The American journal of pathology 2020 Jan;190(1):93-107
Live-Cell Mesothelioma Biobank to Explore Mechanisms of Tumor Progression.
Oehl K, Kresoja-Rakic J, Opitz I, Vrugt B, Weder W, Stahel R, Wild P, Felley-Bosco E
Frontiers in oncology 2018;8:40
Frontiers in oncology 2018;8:40
Efficacy of Anti-mesothelin Immunotoxin RG7787 plus Nab-Paclitaxel against Mesothelioma Patient-Derived Xenografts and Mesothelin as a Biomarker of Tumor Response.
Zhang J, Khanna S, Jiang Q, Alewine C, Miettinen M, Pastan I, Hassan R
Clinical cancer research : an official journal of the American Association for Cancer Research 2017 Mar 15;23(6):1564-1574
Clinical cancer research : an official journal of the American Association for Cancer Research 2017 Mar 15;23(6):1564-1574
Combining Local Immunotoxins Targeting Mesothelin with CTLA-4 Blockade Synergistically Eradicates Murine Cancer by Promoting Anticancer Immunity.
Leshem Y, O'Brien J, Liu X, Bera TK, Terabe M, Berzofsky JA, Bossenmaier B, Niederfellner G, Tai CH, Reiter Y, Pastan I
Cancer immunology research 2017 Aug;5(8):685-694
Cancer immunology research 2017 Aug;5(8):685-694
Malignant Mesothelioma Effusions Are Infiltrated by CD3(+) T Cells Highly Expressing PD-L1 and the PD-L1(+) Tumor Cells within These Effusions Are Susceptible to ADCC by the Anti-PD-L1 Antibody Avelumab.
Khanna S, Thomas A, Abate-Daga D, Zhang J, Morrow B, Steinberg SM, Orlandi A, Ferroni P, Schlom J, Guadagni F, Hassan R
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2016 Nov;11(11):1993-2005
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2016 Nov;11(11):1993-2005
Reduced Shedding of Surface Mesothelin Improves Efficacy of Mesothelin-Targeting Recombinant Immunotoxins.
Awuah P, Bera TK, Folivi M, Chertov O, Pastan I
Molecular cancer therapeutics 2016 Jul;15(7):1648-55
Molecular cancer therapeutics 2016 Jul;15(7):1648-55
Mesothelin Expression in Advanced Gastroesophageal Cancer Represents a Novel Target for Immunotherapy.
Illei PB, Alewine C, Zahurak M, Cowan ML, Montgomery E, Hassan R, Xiang L, Pastan I, Kelly RJ
Applied immunohistochemistry & molecular morphology : AIMM 2016 Apr;24(4):246-52
Applied immunohistochemistry & molecular morphology : AIMM 2016 Apr;24(4):246-52
Megakaryocytic potentiating factor and mature mesothelin stimulate the growth of a lung cancer cell line in the peritoneal cavity of mice.
Zhang J, Bera TK, Liu W, Du X, Alewine C, Hassan R, Pastan I
PloS one 2014;9(8):e104388
PloS one 2014;9(8):e104388
Efficacy of RG7787, a next-generation mesothelin-targeted immunotoxin, against triple-negative breast and gastric cancers.
Alewine C, Xiang L, Yamori T, Niederfellner G, Bosslet K, Pastan I
Molecular cancer therapeutics 2014 Nov;13(11):2653-61
Molecular cancer therapeutics 2014 Nov;13(11):2653-61
Loss of mesothelin expression by mesothelioma cells grown in vitro determines sensitivity to anti-mesothelin immunotoxin SS1P.
Zhang J, Qiu S, Zhang Y, Merino M, Fetsch P, Avital I, Filie A, Pastan I, Hassan R
Anticancer research 2012 Dec;32(12):5151-8
Anticancer research 2012 Dec;32(12):5151-8
In vivo imaging of human malignant mesothelioma grown orthotopically in the peritoneal cavity of nude mice.
Feng M, Zhang J, Anver M, Hassan R, Ho M
Journal of Cancer 2011 Mar 1;2:123-31
Journal of Cancer 2011 Mar 1;2:123-31
The development and characterization of a human mesothelioma in vitro 3D model to investigate immunotoxin therapy.
Xiang X, Phung Y, Feng M, Nagashima K, Zhang J, Broaddus VC, Hassan R, Fitzgerald D, Ho M
PloS one 2011 Jan 31;6(1):e14640
PloS one 2011 Jan 31;6(1):e14640
No comments: Submit comment
Supportive validation
- Submitted by
- Rockland Immunochemicals, Inc. (provider)
- Main image
- Experimental details
- Immunohistochemistry using Rockland's anti-mesothelin antibodies to detect mesothelin in PEFF human tissue sections treated by antigen retrieval methods. Anti-mesothelin primary antibodies were used to label these sections as follows: C, MAb MB; and D, MAb MN. Reprinted with permission fromClin.Cancer Res. 11(16):5840-6.
- Validation comment
- Immunohistochemistry
